Italia markets open in 5 minutes

Kala Pharmaceuticals, Inc. (0JQ2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
15,40+13,68 (+794,31%)
Alla chiusura: 5:56PM GMT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 131,500 shares of Kala Pharmaceuticals common stock to three new employees in connection with the Company’s acquisition of Combangi

  • GlobeNewswire

    Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    -- Achieved $3.1 Million in Net Revenue in 3Q 2021 ---- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021-- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio ---- Conference Call and Webcast at 10:30 a.m. ET -- WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported

  • GlobeNewswire

    Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

    -- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial ---- Kala expects to initiate Phase 2/3 trial in 3Q 2022 ----Mark S. Blumenkranz, M.D., Professor Emeritus in the Department of Ophthalmology at Stanford University, appointed to Kala’s Board of Directors ---- Management to host co